Older patients with cancer are at risk for increased side effects of treatment. Our goal was to inform treatment for older patients by analyzing the relationship between chemotherapy regimen and hospitalization among older women receiving palliative cytotoxic chemotherapy for breast cancer. METHOD: We identified women aged 66-99 years with stage IV de novo breast cancer diagnosed between 2010 and 2013 who received any of the 10 most common cytotoxic chemotherapy-containing regimens in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The primary outcome was hospitalization or death within 30 days of starting a new line of chemotherapy. Generalized linear mixed effects models with patient-specific random effects were used for multivariable analysis of the association between chemotherapy regimen and this outcome. Additional covariates included number of prior lines of therapy; time since diagnosis; hormone receptor and HER2 status; sites of metastatic disease; and age, race, and marital status. The unit of analysis was each new line of chemotherapy. RESULTS: Of 972 lines of chemotherapy initiated among 693 patients, 188 (19%) were followed by hospitalization or death within 30 days. After adjustment, there was significant variation in this outcome by chemotherapy regimen (P = .03); compared with capecitabine, hospitalization/death rates were higher with cyclophosphamide + docetaxel (odds ratio [OR] 
INTRODUCTION
Breast cancer is an age-associated disease. 1 The median age at diagnosis is 62 years, and among patients who die of breast cancer, the median age at death is 68 years. 2 Elderly patients have been underrepresented in clinical trials, [3] [4] [5] and those who are included may be healthier than the general population of elderly patients. 6 Understanding the benefits and risks of therapy in this population therefore requires a real-world assessment of adverse event patterns.
For patients who have metastatic breast cancer, which cannot be cured, palliative-intent systemic therapy is the mainstay of treatment. Regimens that include cytotoxic chemotherapy are the treatment of choice for patients with hormone receptor-negative disease and patients with hormone receptor-positive disease who have exhausted endocrine therapy options. 7 Chemotherapy for metastatic cancer can prolong survival but is associated with important toxicities. Geriatric assessment tools have been applied for risk stratification in elderly patients, but most oncologists have not used these tools in clinical decision-making. 6, 8 Among patients receiving adjuvant chemotherapy for breast cancer, hospitalization rates are substantially higher in older patients than in patients under 65 years of age, and these rates vary significantly by treatment regimen. 9 In the metastatic setting, it is even more important to understand the risks of specific chemotherapy regimens, given the palliative intent of treatment.
Cancer December 15, 2018 To address this need, we conducted a retrospective cohort study to evaluate the association between treatment regimen and adverse event rates, as measured by 30-day hospitalization or death, among older patients receiving cytotoxic chemotherapy for stage IV breast cancer.
PATIENTS AND METHODS

Study Design
We conducted a retrospective study of older patients with stage IV breast cancer who had Medicare fee-forservice coverage. The data source was the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, which contains linked cancer registry and administrative data. 10 
Patient Cohort
We defined a cohort of women who were diagnosed with stage IV de novo breast cancer between 2010 and 2013;
we did not attempt to analyze patients who had early stage disease with subsequent distant recurrence, given the challenges inherent in defining a cohort of patients with recurrent distant metastatic disease using claims data alone. 11 We required at least 12 months of continuous Medicare parts A (inpatient care) and B (outpatient care) fee-for-service coverage before diagnosis to calculate a comorbidity score. Additional criteria included fee-forservice Medicare parts A and B coverage after diagnosis to capture treatment and hospitalization data; an index breast cancer representing a first primary cancer with a known diagnosis date; age 66-99 years at diagnosis; diagnosis before death; and known breast cancer histology. We further restricted the study to patients who received one of the 10 most common chemotherapy regimens to analyze adverse event rates by regimen. For patients meeting these criteria, treatment patterns, hospitalization rates, and mortality were assessed during a follow-up period defined as the time until death, loss of continuous fee-for-service Medicare parts A and B coverage, or the end of available data on December 31, 2014.
Outcome Variables
The unit of analysis was each treatment regimen containing at least 1 cytotoxic chemotherapy agent. Our outcome of interest was the composite of hospitalization or death during the 30 days following initiation of each regimen.
Independent Variables
The key independent variable was the chemotherapy regimen corresponding to each line of therapy analyzed. A line of therapy was defined as a group of drugs, each of which were initiated within 3 weeks of the first drug in the group, and at least 1 of which was a cytotoxic chemotherapy agent; each line could contain 1 or more drugs. Additional independent variables included the number of prior lines of therapy before the line under analysis; months since diagnosis of breast cancer; age at diagnosis; race/ethnicity; marital status; comorbidity as measured by the Klabunde modification of the Charlson comorbidity index 12, 13 (with ascertainment dating from 12 months before diagnosis to 30 days before diagnosis); hormone receptor status (estrogen receptor [ER]-and/or progesterone receptor [PR]-positive; ER-and/or PR-negative; or unknown); HER2/neu status (positive, negative, borderline, or unknown); and metastatic sites encoded in SEER (brain, lung, liver, and or/bone).
Data Analysis
The unit of analysis was each line of chemotherapy. Patients who received more than 1 line of chemotherapy were therefore represented more than once. If patients survived at least 30 days after initiating a line of chemotherapy but lost continuous Medicare coverage or reached the end of the follow-up period (December 31, 2014) within that period, that line of therapy was excluded from the analysis. Analyses were performed using generalized linear mixed effects models with a random effect for each patient to account for clustering within patients who received more than 1 line of chemotherapy.
Analyses were performed using R (version 3.3.3) and SAS (version 9.4) software.
Human Subjects Research
This analysis was based on secondary data, which did not include personal identifiers. The analysis was submitted to the University of Texas MD Anderson Cancer Center Institutional Review Board and the University of Texas Health Sciences Center Committee for Protection of Human Subjects (HSC-SPH-17-0227) and received institutional review board exemptions from both institutions.
RESULTS
Patient Characteristics
We identified 693 patients who met criteria for inclusion in the study; these patients received 972 lines of chemotherapy ( Fig. 1 , Table 1 ). Characteristics of the cohort are detailed in Table 1 . The mean age at diagnosis was 74 years. Most patients (67%) had hormone receptor-positive disease according to SEER registry data. Nineteen percent had tumors known to be HER2/neu-positive.
Cancer December 15, 2018 The median overall survival in this cohort of treated patients with stage IV disease was 28.4 months (95% CI, 25.9-32.0 months) (Fig. 2) .
Hospitalization or Death Following Cytotoxic Chemotherapy
Among the 972 lines of chemotherapy for this cohort, 188 (19%) were associated with an inpatient hospitalization, skilled nursing facility stay, long-term care facility stay, or death within 30 days of starting therapy; 40 (4%) were followed by death within 30 days. In a univariable analysis, there was no statistically significant variation in the rate of the primary outcome by chemotherapy regimen, ranging from 14% for capecitabine to 33% for gemcitabine (P = .09). Associations between other factors and the composite of hospitalization or death are detailed in Table 2 . In a separate analysis of 218 patients who received 347 lines of chemotherapy with regimens that were not among the 10 most common, the proportion followed by hospitalization or death within 30 days of starting treatment was lower than that in our primary analysis (N = 50 [14%]).
After adjustment for number of lines of prior chemotherapy and for time between initial diagnosis and initiation of the line of therapy under analysis, chemotherapy regimen was significantly associated with the rate of 30-day hospitalization or death (P = .03) ( . In a sensitivity analysis that additionally adjusted for the number of prior inpatient stays within 60 days before initiation of a new line of chemotherapy, the association between regimen and the chance of hospitalization or death within 30 days after initiating a new line of therapy persisted (P = .02).
DISCUSSION
In this analysis of older women with stage IV breast cancer, initiation of a new of cytotoxic chemotherapy was associated with a nearly 20% rate of 30-day hospitalization or death, and this rate varied significantly by regimen. Chemotherapy regimen remained associated with this outcome even after adjustment for demographic and clinical factors, including number of lines of prior therapy. Palliative-intent cytotoxic chemotherapy requires special consideration among elderly patients, who are underrepresented in clinical trials.
14 These patients suffer from a greater burden of comorbidity and frailty, and appropriate oncologic management requires the consideration of both chronological age and functional status. 15 At the same time, elderly patients may be vulnerable to undertreatment, 14 and among elderly patients with breast cancer, geographic disparities in treatment patterns have been associated with differences in outcomes. 16 The results of our study may inform assessment of risk among patients considering a new line of palliative chemotherapy for breast cancer.
Our analysis had several limitations. Importantly, it is possible that unmeasured confounding related to the severity of underlying breast cancer could have impacted these results, particularly in the case of doublet chemotherapy. Patients with imminently threatening disease might have received chemotherapy regimens deemed likely to confer a greater potential benefit, albeit at a greater risk for toxicity. Additionally, patients who have progressed through prior lines of more tolerable therapy might be more likely to experience hospitalization or death after new chemotherapy because of more severe underlying disease. Furthermore, our analysis did not attempt to use claims data to distinguish between hospitalization due solely to therapeutic toxicity and hospitalization due solely to underlying disease progression, since hospitalization for a combination of these 2 events may be common. Still, we adjusted for the number of lines of prior therapy and the time from diagnosis to initiation of therapy, which would likely have mitigated these effects. Cancer December 15, 2018 We focused on patients who had stage IV de novo disease, since existing algorithms to define recurrence using claims data have suboptimal performance characteristics, 11 and distinguishing potentially curable local recurrence from incurable distant recurrence may not be straightforward. Approximately 5% of patients Cancer December 15, 2018 with newly diagnosed breast cancer have stage IV disease. 18 It is therefore not clear to what extent our results can be extrapolated to patients with recurrent as opposed to de novo metastatic disease, since treatment patterns and patient characteristics may differ in the 2 populations.
Finally, any chemotherapy given without billing for the drug would not have been captured by our analysis. However, given the cost of chemotherapy, it is likely billed the vast majority of the time for patients with Medicare coverage. Treatment given via a clinical trial might also not be billed, but a very small proportion of patients participates in trials on a population basis.
In conclusion, our analysis of older patients newly diagnosed with stage IV breast cancer revealed that treatment toxicity, as measured by hospitalization and death rates soon after initiating a new line of therapy, differed among cytotoxic regimens. These differences may inform treatment decision-making for this population. 
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